Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies.

Autor: Chan ASH; HiberCell Inc., Roseville, MN, United States.; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Kangas TO; HiberCell Inc., Roseville, MN, United States.; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Qiu X; HiberCell Inc., Roseville, MN, United States.; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Uhlik MT; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Fulton RB; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Ottoson NR; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Gorden KB; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Yokoyama Y; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Danielson ME; HiberCell Inc., Roseville, MN, United States.; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Jevne TM; HiberCell Inc., Roseville, MN, United States.; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Michel KS; HiberCell Inc., Roseville, MN, United States.; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Graff JR; Biothera Pharmaceuticals Inc., Eagan, MN, United States., Bose N; HiberCell Inc., Roseville, MN, United States.; Biothera Pharmaceuticals Inc., Eagan, MN, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 May 26; Vol. 12, pp. 869078. Date of Electronic Publication: 2022 May 26 (Print Publication: 2022).